Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02108652 · OUTCOME

Percentage of Participants Positive for Anti-therapeutic Antibodies (ATA) to Atezolizumab

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) · Source last updated 2024-03-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Day 1 of all cycles (Cycle length = 21 days) and at treatment discontinuation (data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)

Analysis population: Cohort 2 Safety Evaluable Population. Here, number of participants analyzed = participants for whom ATA samples were available.

Groups in this outcome

Cohort 2: Participants With Second-line or Beyond Treatments

Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 2: Participants With Second-line or Beyond Treatments276

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 2: Participants With Second-line or Beyond Treatments42.4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        42.4
denoms
  1. counts
    1. group Id
      OG000
      value
      276
    units
    Participants
groups
  1. description
    Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
    id
    OG000
    title
    Cohort 2: Participants With Second-line or Beyond Treatments
param Type
NUMBER
population Description
Cohort 2 Safety Evaluable Population. Here, number of participants analyzed = participants for whom ATA samples were available.
reporting Status
POSTED
time Frame
Day 1 of all cycles (Cycle length = 21 days) and at treatment discontinuation (data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)
title
Percentage of Participants Positive for Anti-therapeutic Antibodies (ATA) to Atezolizumab
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice